GlaxoSmithKline has filed charges against the U.S. Patent and Trademark Office for imposing new rules that would allegedly damage around 100 of the drug giant's unapproved patent applications. The PTO said the new rules, which take effect Nov. 1, would make patent application more "efficient by encouraging applicants to use greater precision in describing the scope of their inventions." A GSK spokeswoman said the regulations would "stifle innovation because they would severely limit our ability to fully claim our inventions."

Related Summaries